Health Center Asks Court to Reject Drug Maker Briefs in Challenge to 340B Patient Definition

Genesis
Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.
A health center challenging the government’s 340B program patient definition in a federal district court recently asked a federal judge [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Provider-PhRMA Coalition Adds Civil Rights Group

ASAP 340B
ASAP 340B, a coalition of a drug industry trade group and a community health center organization, added a civil rights group to its membership.
An alliance led by a powerful drug industry trade group and community health center organization that is pushing for 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drug Maker Owes 340B Providers Repayment, HRSA Pending Audit Finds

Nephron Pharmaceuticals
A HRSA fiscal year 2023 audit tentatively found that drug maker Nephron Pharmaceuticals owes 340B repayments to providers.
The first posted fiscal year 2023 audit of a drug maker tentatively found the company owes repayments to providers. The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Drugs Among Those at Tornado-Hit Facility Requiring Direct Purchase

Pfizer headquarters
Pfizer has limited multiple 340B-eligible drugs to direct purchase after a tornado damaged one of the drug maker's manufacturing facilities.
Federal officials confirmed that 340B-eligible drugs are among the 12 medications pharmaceutical manufacturer Pfizer has limited to direct purchase after [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Share of Retail Pharmacies that Contract with ‘Core’ 340B Safety-Net Facilities Fell Over Time, Study Finds

JAMA contract pharmacy study
There has been a decline in the share of retail pharmacies that contract with 340B "core safety-net facilities," according to a JAMA Health Forum study.
The proportion of retail contract pharmacies in the 340B program that contract exclusively with “core safety-net” facilities fell from 95% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HHS Asks Court to Deny Injunction Against Medicare Drug Price Negotiations

Dayton v. Becerra
HHS asked the U.S. District Court in Dayton, Ohio to deny a preliminary injunction that would prevent Medicare drug price negotiations.
The U.S. Department of Health and Human Services (HHS) asked a federal court to deny a preliminary injunction sought by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Pfizer Changes Costly Cardiac Drugs’ Access Rules for 340B Providers

Pfizer headquarters
Pfizer has limited multiple 340B-eligible drugs to direct purchase after a tornado damaged one of the drug maker's manufacturing facilities.
Drug manufacturer Pfizer is changing how healthcare providers access 340B pricing on two expensive, related heart medicines, effective Nov. 1, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Two Drug Makers Post Manufacturer Notices for 340B Overcharges

Manufacturer notices
Meitheal Pharmaceuticals and Purdue Pharma are each sending 340B covered entities refunds for overcharges totaling $100 or more.
Two drug manufacturers are sending 340B covered entities refunds for overcharges totaling $100 or more, according to public filings posted [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Lobbying Activity Experiences Historic Surge

Capitol building
Key House Republicans on Tuesday introduced long-awaited—and contentious—legislation to overhaul the 340B program.
The hiring of lobbyists in the congressional legislative fight over 340B was dominated by pharmaceutical firms and provider-manufacturer alliances in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Major Drug Company Sues Louisiana Over 340B Contract Pharmacy Law

AstraZeneca headquarters
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
Drug manufacturer AstraZeneca, one of the first companies to place restrictions on 340B discounts in the contract pharmacy setting, has [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live